🚀 VC round data is live in beta, check it out!
Hikma Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hikma Pharmaceuticals and similar public comparables like Legend Biotech, Amoytop Biotech, Indivior Pharmaceuticals, NewAmsterdam Pharma and more.
Hikma Pharmaceuticals Overview
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Founded
2005
HQ
Employees
9.5K
Website
Sectors
Financials (LTM)
EV
$5B
Hikma Pharmaceuticals Financials
Hikma Pharmaceuticals reported last 12-month revenue of $3B and EBITDA of $846M.
In the same LTM period, Hikma Pharmaceuticals generated $2B in gross profit, $846M in EBITDA, and $404M in net income.
Revenue (LTM)
Hikma Pharmaceuticals P&L
In the most recent fiscal year, Hikma Pharmaceuticals reported revenue of $3B and EBITDA of $845M.
Hikma Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $846M | XXX | $845M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $404M | XXX | $402M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hikma Pharmaceuticals Stock Performance
Hikma Pharmaceuticals has current market cap of $4B, and enterprise value of $5B.
Market Cap Evolution
Hikma Pharmaceuticals' stock price is $18.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $4B | -0.7% | XXX | XXX | XXX | $1.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHikma Pharmaceuticals Valuation Multiples
Hikma Pharmaceuticals trades at 1.6x EV/Revenue multiple, and 6.2x EV/EBITDA.
EV / Revenue (LTM)
Hikma Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Hikma Pharmaceuticals has market cap of $4B and EV of $5B.
Equity research analysts estimate Hikma Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hikma Pharmaceuticals has a P/E ratio of 9.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBIT | 7.2x | XXX | 7.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | 3.7x | XXX | XXX | XXX |
| P/E | 9.7x | XXX | 9.8x | XXX | XXX | XXX |
| EV/FCF | 17.7x | XXX | 22.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hikma Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hikma Pharmaceuticals Margins & Growth Rates
Hikma Pharmaceuticals' revenue in the last 12 month grew by 4%.
Hikma Pharmaceuticals' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Hikma Pharmaceuticals' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hikma Pharmaceuticals' rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hikma Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hikma Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hikma Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Legend Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Amoytop Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Indivior Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| NewAmsterdam Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ipca Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hikma Pharmaceuticals M&A Activity
Hikma Pharmaceuticals acquired XXX companies to date.
Last acquisition by Hikma Pharmaceuticals was on XXXXXXXX, XXXXX. Hikma Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hikma Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHikma Pharmaceuticals Investment Activity
Hikma Pharmaceuticals invested in XXX companies to date.
Hikma Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Hikma Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hikma Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hikma Pharmaceuticals
| When was Hikma Pharmaceuticals founded? | Hikma Pharmaceuticals was founded in 2005. |
| Where is Hikma Pharmaceuticals headquartered? | Hikma Pharmaceuticals is headquartered in United Kingdom. |
| How many employees does Hikma Pharmaceuticals have? | As of today, Hikma Pharmaceuticals has over 9K employees. |
| Who is the CEO of Hikma Pharmaceuticals? | Hikma Pharmaceuticals' CEO is Said Darwazah. |
| Is Hikma Pharmaceuticals publicly listed? | Yes, Hikma Pharmaceuticals is a public company listed on London Stock Exchange. |
| What is the stock symbol of Hikma Pharmaceuticals? | Hikma Pharmaceuticals trades under HIK ticker. |
| When did Hikma Pharmaceuticals go public? | Hikma Pharmaceuticals went public in 2005. |
| Who are competitors of Hikma Pharmaceuticals? | Hikma Pharmaceuticals main competitors are Legend Biotech, Amoytop Biotech, Indivior Pharmaceuticals, NewAmsterdam Pharma. |
| What is the current market cap of Hikma Pharmaceuticals? | Hikma Pharmaceuticals' current market cap is $4B. |
| What is the current revenue of Hikma Pharmaceuticals? | Hikma Pharmaceuticals' last 12 months revenue is $3B. |
| What is the current revenue growth of Hikma Pharmaceuticals? | Hikma Pharmaceuticals revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Hikma Pharmaceuticals? | Current revenue multiple of Hikma Pharmaceuticals is 1.6x. |
| Is Hikma Pharmaceuticals profitable? | Yes, Hikma Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hikma Pharmaceuticals? | Hikma Pharmaceuticals' last 12 months EBITDA is $846M. |
| What is Hikma Pharmaceuticals' EBITDA margin? | Hikma Pharmaceuticals' last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Hikma Pharmaceuticals? | Current EBITDA multiple of Hikma Pharmaceuticals is 6.2x. |
| What is the current FCF of Hikma Pharmaceuticals? | Hikma Pharmaceuticals' last 12 months FCF is $298M. |
| What is Hikma Pharmaceuticals' FCF margin? | Hikma Pharmaceuticals' last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Hikma Pharmaceuticals? | Current FCF multiple of Hikma Pharmaceuticals is 17.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.